Top

Published in:

01-04-2009 | Case Report

Steatorrhoea complicating post-infectious diarrhoea in a renal transplant patient on mycophenolate mofetil therapy

Authors: Senyo Tagboto, Farman Akhtar

Published in: Clinical and Experimental Nephrology | Issue 2/2009

Abstract

Mycophenolate mofetil (MMF) is licensed as a prophylaxis in combination therapy to prevent renal transplant rejection. Gastrointestinal side effects are fairly common and include diarrhoea, abdominal discomfort, nausea, vomiting, gastritis and constipation. This drug has recently been described as causing villous atrophy, nutrient malabsorption and colonic mucosal changes. We present a case of reversible steatorrhoea occurring in a patient treated with MMF following an episode of infections diarrhoea.

Davies NM, Grinyo J, Heading R, Maes B, Meier-Kriesche H, Oellerich M. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Neph Dial Transplant. 2007;22:2440–8.CrossRef

Bunnapradist S, Neri L, Wong W, Lentine KL, Burroughs TE, Pinsky BW, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis. 2008;51:478–86.CrossRefPubMed

Kamar N, Faure P, Dupuis E, Coinault O, Joseph-Hein K, Durand D, et al. Villous atrophy induced by mycophenolate mofetil in renal transplant patients. Transplant Int. 2004;17:463–7.CrossRef

Ducloux D, Ottigon Y, Semhoun-Doucloux S, Labbe S, Saint-Hillier Y, Miguet JP, et al. Mycophenolate mofetil-induced villous atrophy. Transplantation. 1998;66:1115–6.CrossRefPubMed

Pally C, Tanner M, Rizvi H, Papageorgiou C, Schuurman HJ. Tolerability profile of sodium mycophenolate (ERL0800 and mycophenolate mofetil with and without cyclosporine (neoral) in the rat. Toxicology. 2001;157:207–15.CrossRefPubMed

Maes BD, Dalle I, Geboes K, Oellerich M, Armstrong VW, Evenepoel P, Geypens B, Kuypers D, Shipkova M, Geboes K, Vanrenterghem YF. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation. 2003;75(5):665–72.CrossRefPubMed

Dalle IJ, Maes BD, Geboes KP, Lemahieu W, Geboes K. Crohn’s-like changes in the colon due to mycophenolate? Colorectal Dis. 2005;7(1):27–34.CrossRefPubMed

Moelle DD. Steatorrhoea associated with meclofenamate sodium therapy. Am J Gastroenterol. 1987;82:1320–1.

Rahman F, Cain GD. Drug-induced malabsorption: a review. South Med J. 1973;66:724–5.CrossRefPubMed

10.

Wilson DW, Wilson HC. Studies in vitro of the digestion and absorption of purine nucleotides by the intestine. J Biol Chem. 1962;237:1643–7.PubMed

11.

Shipkova M, Spielbauer B, Voland A, Gröne HJ, Armstrong VW, Oellerich M, et al. cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. Transplantation. 2004;78:1145–52.CrossRefPubMed

12.

Fine KD, Fordtan JS. The effect of diarrhoea on fecal fat excretion. Gastroenterology. 1992;102:1936–9.CrossRefPubMed

13.

Laskin B, Goebel J. Clinically “silent” weight loss associated with mycophenolate mofetil in pediatric renal transplant recipients. Pediatr Transplantation. 2008;12:113–6.CrossRef

14.

Walters JRF. Investigation of gastrointestinal function. In: Warrel DA, Cox TM, Firth JD, Denz EJ, editors. Oxford textbook of medicine. Oxford, UK:Oxford University Press: 2003. p. 504.

Title: Steatorrhoea complicating post-infectious diarrhoea in a renal transplant patient on mycophenolate mofetil therapy
Authors: Senyo Tagboto
Farman Akhtar
Publication date: 01-04-2009
Publisher: Springer Japan
Published in: Clinical and Experimental Nephrology / Issue 2/2009
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-008-0109-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Steatorrhoea complicating post-infectious diarrhoea in a renal transplant patient on mycophenolate mofetil therapy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

A case of lymphangioleiomyomatosis with membranous nephropathy and likely systemic lupus

Cyclosporine therapeutic monitoring with CMAX in kidney transplant recipients: racial considerations

Autonomic neuropathy in hemodialysis patients: questionnaires versus clinical tests

Non-convulsive status epilepticus following antibiotic therapy as a cause of unexplained loss of consciousness in patients with renal failure

Chronic diarrhea caused by Hymenolepis nana in a renal transplant recipient

Acute renal failure as the presenting feature of leukaemic infiltration in chronic lymphocytic leukaemia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page